MindMed and Liechtenstein Laboratory in Basel, Switzerland Release First LSD Pharmacogenetic Data for Personalized Dosage Guide
NEW YORK, May 26, 2021 / PRNewswire / – MindMed (Nasdaq: MNMD) (NEO: MMED) (DE: MMQ), a leading psychedelic medicine biotechnology company, today announced the release of the first pharmacogenetic data on LSD to help customize dosing . The study was the result of a pooled secondary analysis of four Phase 1 studies that each used a randomized, double-blind, placebo-controlled crossover design that were conducted at the University Hospital Basel. Basel, Switzerland.
The results of this study indicate that pharmacogenetic testing prior to LSD assisted treatment can inform individual patient level LSD dose selection.
Dr. Matthias Liechtenstein said: “These are the first data on the pharmacogenetics of LSD. The results indicate that an assay of a patient’s metabolic function by CYP2D6 phenotyping and genotyping can be used to adjust the dose of LSD. This information is important for further development of LSD into a drug and could ultimately help personalize patient treatment. “
In vitro studies indicate that the metabolic isoforms of cytochrome P450, in particular CYP2D6, CYP1A2 and CYP2C9, are involved in the metabolism of LSD, but clinical studies on the effects of variations of these isoforms have not been conducted. .
This study examined the influence of genetic polymorphisms of important CYP enzymes on the pharmacokinetics and acute psychological effects of LSD in healthy subjects. Common genetic variants of CYPs, including CYP2D6, CYP1A2, CYP2C9, CYP2C19 and CYP2B6, were identified in 81 healthy subjects in four randomized, double-blind, placebo-controlled phase 1 studies.
The genetically determined CYP2D6 functionality significantly influenced the pharmacokinetics of LSD. Specifically, individuals without functional CYP2D6, known as poor metabolizers, had longer and approximately 75% higher LSD half-lives of the parent drug and the major metabolite, 2-oxo-3-hydroxy-LSD. , area under the plasma blood concentration curve relative to carriers of functional CYP2D6. Additionally, non-functional CYP2D6 metabolisers exhibited increased acute psychological effects and longer subjective effects durations compared to functional CYP2D6 metabolisers.
No effects on the pharmacokinetics or acute effects of LSD were observed with other variations of CYP. These results indicate that specific genetic polymorphisms of CYP2D6 significantly influence the pharmacokinetic and subjective effects of LSD.
The study “Genetic influence of CYP2D6 on the pharmacokinetics and acute subjective effects of LSD in a pooled analysis” has been published in Nature Scientific Reports and the full text can be viewed from the editors at: https: // www .nature.com / articles / s41598-021-90343-y.
Executive Chairman of MindMed, Dr Miri Halperin Wernli said, “The psychedelic experience can be conceptualized as the facilitated transformative encounter between one’s fears and desires with the universe and its web of living processes. This work with Professor Liechtenstein, indicating that genetic polymorphisms of CYP2D6 significantly influence the pharmacokinetic and subjective effects of LSD, is an illustration that biological and psychological transformation processes can be deeply intertwined. When LSD is the chosen key to unlock an opportunity for psycho-transformation and growth, individual parameters such as one’s own rate of metabolism and bio-transformation must be carefully understood and taken into consideration in order to enable the effect of transformation to happen in the most powerful and secure way. “
MindMed is a clinical-stage psychedelic medicine biotechnology company that discovers, develops and deploys psychedelically-inspired drugs and therapies to combat addiction and mental illness. The company is assembling a compelling drug development pipeline of innovative therapies based on psychedelics, including psilocybin, LSD, MDMA, DMT and an ibogaine derivative, 18-MC. The MindMed leadership team brings extensive biopharmaceutical experience to MindMed’s approach to develop the next generation of psychedelically inspired drugs and therapies.
MindMed trades on NASDAQ under the symbol MNMD and on the Canadian stock exchange NEO under the symbol MMED. MindMed is also marketed Germany under the symbol MMQ.
Certain statements contained in this press release concerning the Company constitute “forward-looking information” within the meaning of applicable securities laws and are forward-looking in nature. Forward-looking information is not based on historical facts, but rather on current expectations and projections regarding future events and is therefore subject to risks and uncertainties which could cause actual results to differ materially from expressed future results or implied by forward-looking statements. . These statements can generally be identified by the use of forward-looking terms such as “will”, “may”, “should”, “could”, “intend”, “estimate”, “plan”, “anticipate”, “predict” “,” believe “,” potential “or” continue “, or their negative or similar variations. The forward-looking information contained in this press release includes statements regarding the genetic influence of CYP2D6 on the pharmacokinetics, effects subjects of LSD, the results of phase 1 studies of the Basel-Liechtenstein university laboratory, the metabolic function of patients, the development of LSD into a drug, the potential effect of changes in CYP2D6, CYP1A2 and CYP2C9, and plans for ‘anticipated future business and operations of the Company, including the development of psychedelic-inspired drugs and experiential therapies. Although the Company believes that the expectations reflected in this forward-looking information are r This information is easily accessible and involves risks and uncertainties, and you should not place undue reliance on this information, as unknown or unforeseeable factors could have material adverse effects on future results and performance. or the achievements of the company. There are many risks and uncertainties that could cause actual results and the company’s plans and objectives to differ materially from those expressed in forward-looking information, including negative cash flow history; limited operating history; occurrence of future losses; availability of additional capital; lack of income produced; compliance with laws and regulations; difficulty associated with research and development; risks associated with clinical trials or studies; increased regulatory review; early stage product development; risks associated with clinical trials; regulatory approval process; novelty of the psychedelic-inspired drug industry; as well as the risk factors discussed or referred to herein and the risks described under the headings “Risk Factors” in the documents filed by the Company with the securities regulators of all provinces and territories. of Canada and available under the Company Profile on SEDAR at www.sedar.com and with the United States Securities and Exchange Commission on EDGAR at www.sec.gov. If one or more of these risks or uncertainties materialize, or if the assumptions underlying the forward-looking information prove to be incorrect, actual results and future events could differ materially from those anticipated in such information. Although the company has attempted to identify risks, uncertainties and important factors that could cause actual results to differ materially, there may be others that cause results not to meet expectations. , estimates or intentions. This information, as well as all subsequent written and oral forward-looking information, is based on management’s estimates and opinions on the dates on which it is made and is expressly qualified in its entirety by this notice. Unless required by law, the Company does not intend and assumes no obligation to update this forward-looking information.
SOURCE Mind Medicine (MindMed) Inc.